Cellectis SA
ALCLS
Company Profile
Business description
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Contact
8, rue de la Croix Jarry
Paris75013
FRAT: +33 181691600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
222
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,826.60 | 15.30 | -0.17% |
| CAC 40 | 7,696.27 | 58.28 | -0.75% |
| DAX 40 | 23,787.45 | 146.68 | -0.61% |
| Dow JONES (US) | 44,828.53 | 344.11 | 0.77% |
| FTSE 100 | 8,822.91 | 0.29 | -0.00% |
| HKSE | 23,852.13 | 63.93 | -0.27% |
| NASDAQ | 20,601.10 | 207.97 | 1.02% |
| Nikkei 225 | 39,582.00 | 228.88 | -0.57% |
| NZX 50 Index | 12,764.95 | 1.65 | -0.01% |
| S&P 500 | 6,279.35 | 51.93 | 0.83% |
| S&P/ASX 200 | 8,588.00 | 15.00 | -0.17% |
| SSE Composite Index | 3,466.83 | 5.49 | -0.16% |